晚期帕金森病的运动障碍和疼痛:来自第3b期,开放标签,随机化DYSCOVER研究的后期分析
Eric Freire-Alvarez1, Paola Vanni2, Egon Kurča3
1Neurology Department, University General Hospital of Elche, Carrer Almazara, 11, 03203, Elche, Alicante, Spain. dr.freyre@gmail.com.
Neurology and therapy
|February 12, 2024
概括
利沃多巴-卡比多巴肠凝 (LCIG) 显著改善了帕金森病患者的动力障碍和疼痛. 这些改善与更好的健康相关的生活质量相关,突出显示了运动障碍的影响.
科学领域:
- 神经学 神经学
- 临床试验 临床试验
- 帕金森病研究 帕金森病研究
背景情况:
- DYSCOVER研究 (NCT02799381) 是一项3b期试验,该试验比较了乐伏多巴-卡比多巴肠凝 (LCIG) 与帕金森病 (PD) 患者的优化医疗治疗 (OMT).
- 基线特征包括高动障碍负担,由统一动障碍评分表 (UDysRS) 评分≥30来定义.
研究的目的:
- 检查PD患者的功能障碍,疼痛和健康相关结果之间的相关性.
- 评估运动症状改善与生活质量之间的关系.
主要方法:
- 对DYSCOVER研究数据进行了后期分析.
- 评估了UDysRS,国王帕金森病疼痛量表 (KPPS),PDQ-8和CGI分数之间的相关性.
- 用皮尔森相关系数来量化基线和第12周的关系.
主要成果:
- 在UDysRS和KPPS得分之间发现了中等到强的正相关性 (基线r=0.47,第12周r=0.63).
- 在UDysRS/KPPS和PDQ-8得分之间观察到显著的相关性 (基线r=0.45-0.46,第12周r=0.54-0.64).
- 中等相关性将UDysRS与CGI-S/CGI-C分数联系起来 (基线r=0.41,第12周r=0.47).
结论:
- 在PD患者中,明显的动力障碍,动力障碍和疼痛与健康相关的生活质量有很强的相关性.
- 功能障碍和疼痛的改善与提高生活质量有关.
- 这凸显了帕金森病中麻烦性动力障碍所造成的大量临床负担.
相关概念视频
Parkinson's Disease: Treatment
268
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
268
Parkinson's Disease: Overview
546
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
546


